Overview

To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

Status:
Completed

Trial end date:
2013-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen (BR) of antibacterial drugs as treatment for MDR-TB

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Infectious Diseases BVBA

Treatments:

Bedaquiline
Diarylquinolines